Protocol Ledger

NCT06830421 · Phase III · RECRUITING

Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients

Interventional Phase III clinical trial protocol NCT06830421 sponsored by University Hospital Freiburg in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-09 Enrollment: 340 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06830421
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)340 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06830421
Protocol FieldVerified Registry Value
NCT IdentifierNCT06830421
Consolidated Lead SponsorUniversity Hospital Freiburg
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment340 participants (ESTIMATED)
Registered Start Date2023-08-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06830421
Hospital Research SiteLocationSite Profile
Klinikum Chemnitz gGmbHChemnitz, GermanyOpen Hospital Dossier ->
Universitätsklinikum EssenEssen, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI